Nuance Pharma has announced a deal with DKSH Business Unit Healthcare for commercialization of Bentrio, an API-free, bentonite-based OTC nasal spray for protection against allergens and viruses, in Hong Kong and Macau. Bentrio is currently marketed in several countries in Europe for allergic rhinitis, and in the US, the nasal spray received 510(k) clearance in June 2022 for the treatment of allergic rhinitis.
Bentrio developer Altamira Therapeutics announced in March 2022 that Nuance had acquired the rights to the nasal spray for mainland China, South Korea, Hong Kong, and Macau. Nuance is also developing Verona’s nebulized ensifentrine for the treatment of COPD in China.
DKSH Hong Kong Head of Management and VP, Healthcare, Wai Ting Fong commented, “DKSH is delighted to partner with Nuance Pharma to introduce their innovative product Bentrio. With a broad reach across our different commercial channels, we are committed to driving its expansion in Hong Kong and Macau. Our partnership demonstrates our commitment to offering patients better health and quality of life, in line with DKSH’s purpose to enrich people’s lives, by providing access to healthcare, goods, services, and insights.”
Nuance Pharma CEO Mark G. Lotter said, “This is a significant milestone for Nuance Pharma’s Asia expansion strategy, as we establish commercial capabilities in two additional key markets while delivering innovative, safe, and effective products to the region. Hong Kong is an important gateway to Asia and represents a critical initial step to expand its presence to the region whilst the company prepares for the introduction of its innovative pipeline currently in development. We look forward to a successful and strong partnership with the leading regional leader DKSH, while delivering ever more innovative therapies with high unmet needs in the region in the coming years.”
Read the DKSH press release.
